Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Fertility hope: egg freezing before breast cancer chemo tested in new study

NCT ID NCT02871167

Disease control Sponsor: Centre Oscar Lambret Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether ovarian stimulation and egg or embryo freezing is safe and doable for young women (ages 18–38) with early breast cancer who are about to start chemotherapy. The goal is to help preserve their fertility. Researchers will track how many eggs are collected, the quality of those eggs and embryos, and any side effects from the hormone treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Controlled ovarian hyperstimulation (COH) with recombinant FSH and GnRH agonist trigger, followed by oocyte/embryo cryopreservation
What this could lead to
If successful, this could offer a reliable way for young breast cancer patients to preserve their fertility before starting chemotherapy.
What could go wrong
This is a feasibility study, not a large trial, so results may not apply to all patients. Ovarian stimulation carries a small risk of overstimulation, and not all preserved eggs or embryos will lead to a successful pregnancy later.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

140 people

The number who actually took part.

Started

Dec 2016

Expected to finish

Nov 2034

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 38 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women with histologically proven breast cancer * Aged 18 to 38 years old * Planned adjuvant chemotherapy * No prior chemotherapy * Affiliated to a public health insurance program * Informed consent signed by the patient Exclusion Criteria: * Metastatic breast cancer * Planned neo-adjuvant chemotherapy * Hysterectomy * Exclusive adjuvant hormonotherapy * Positive serology for syphilis, hepatitis B or C, or VIH * Contraindication related to use of r-FSH * Pregnant or breastfeeding patients

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer

Contacts and locations

Locations

  • CHRU Hôpital Jeanne de Flandres

    Lille, 59037, France

  • CHRU Montpellier

    Montpellier, 34295, France

  • CHRU de Nancy

    Nancy, 54000, France

  • CHU La Conception

    Marseille, 13005, France

  • CHU Limoges

    Limoges, 87042, France

  • CHU Lyon

    Lyon, 69229, France

  • CHU REUNION site SUD

    La Réunion, 97410, France

  • CHU Rouen

    Rouen, 76031, France

  • CHU de Caen

    Caen, 14033, France

  • CHU de Dijon

    Dijon, 21079, France

  • Centre Aliénor d'Aquitaine, Hôpital Pellegrin

    Bordeaux, 33076, France

  • Centre François Baclesse

    Caen, 14076, France

  • Centre Georges François LECLERC

    Dijon, 21079, France

  • Centre Henri Becquerel

    Rouen, 76038, France

  • Centre Léon Bérard

    Lyon, 69373, France

  • Centre Oscar Lambret

    Lille, 59020, France

  • Hôpital Antoine Béclère

    Clamart, 92140, France

  • Hôpital Cochin

    Paris, 75014, France

  • Hôpital Jean Verdier

    Bondy, 93140, France

  • Hôpital TENON

    Paris, 75020, France

  • Hôpital Universitaire de Strasbourg

    Strasbourg, 67091, France

  • ICM - Val d'Aurelle

    Montpellier, 34298, France

  • Institut Curie

    Paris, 75005, France

  • Institut Curie

    Saint-Cloud, 92210, France

  • Institut Gustave Roussy

    Villejuif, 94805, France

  • Institut Paoli Calmette

    Marseille, 13273, France

  • Institut de Cancérologie de Lorraine

    Vandœuvre-lès-Nancy, 54519, France

  • Oncopole-CHU Toulouse

    Toulouse, 31059, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.